SCHEMBL6354517

SCHEMBL6354517

O=C(Cl)C(=O)N(c1ccccc1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.58
ALDH1A1 P00352 5/20 0.54
POLB P06746 3/20 0.54
KMT2A Q03164 2/20 0.54
NPC1 O15118 1/20 0.54
HTT P42858 1/20 0.54
RAB9A P51151 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TRPM8 Q7Z2W7 2/20 0.44
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 2/20 0.41
GLA P06280 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11325296 0.86 NPSR1 (0.58) NPSR1ALDH1A1POLBKMT2ANPC1
SCHEMBL11363030 0.80 NPSR1 (0.52) NPSR1ALDH1A1POLBKMT2ANPC1
SCHEMBL11363034 0.80 NPSR1 (0.52) NPSR1ALDH1A1POLBKMT2ANPC1
SCHEMBL9456609 0.80 NPSR1 (0.64) NPSR1ALDH1A1POLBKMT2ANPC1
SCHEMBL310005 0.80 NPSR1 (0.64) NPSR1ALDH1A1POLBKMT2ANPC1
SCHEMBL5580331 0.77 POLB (0.52) NPSR1POLBKMT2ANPC1HTT
SCHEMBL1270501 0.76 NPSR1 (0.58) NPSR1ALDH1A1POLBKMT2ANPC1
SCHEMBL11562411 0.76 KMT2A (0.41) NPSR1ALDH1A1POLBKMT2ANPC1
SCHEMBL812818 0.74 NPSR1 (1.00) NPSR1ALDH1A1POLBKMT2ANPC1
SCHEMBL19778 0.74 NPSR1 (0.70) NPSR1ALDH1A1POLBKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927579-B2 Male contraceptive Amobi, Nnaemkea Ikechukwu (GB) 2015-01-06 US disclosed
US-8927579-B2 Male contraceptive Amobi, Nnaemkea Ikechukwu (GB) 2015-01-06 US disclosed
US-8778968-B2 2014-07-15 US disclosed
US-8778968-B2 2014-07-15 US disclosed
EP-2081974-B1 POLYCARBONATES AND COPOLYCARBONATES WITH IMPROVED METAL ADHESION BAYER MATERIALSCIENCE AG (DE) 2011-02-23 EP disclosed
US-20100029624-A1 Male Contraceptive KING'S COLLEGE LONDON (GB) 2010-02-04 US disclosed
US-20100029624-A1 Male Contraceptive KING'S COLLEGE LONDON (GB) 2010-02-04 US disclosed
US-7547755-B2 (Co)polycarbonates having improved adhesion to metals BAYER MATERIAL SCIENCE AG (DE) 2009-06-16 US disclosed
US-7547755-B2 (Co)polycarbonates having improved adhesion to metals BAYER MATERIAL SCIENCE AG (DE) 2009-06-16 US disclosed
WO-2008037364-A1 POLYCARBONATES AND COPOLYCARBONATES WITH IMPROVED METAL ADHESION BAYER MATERIALSCIENCE AG (DE) 2008-04-03 WO disclosed
US-20080081896-A1 (Co)polycarbonates having improved adhesion to metals COVESTRO DEUTSCHLAND AG (DE) 2008-04-03 US disclosed
US-20080081896-A1 (Co)polycarbonates having improved adhesion to metals COVESTRO DEUTSCHLAND AG (DE) 2008-04-03 US disclosed
US-20050192337-A1 Processes and polymorphs of diaryl-indolone galr3 antagonists H. LUNDBECK A/S (DK) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192337-A1 Processes and polymorphs of diaryl-indolone galr3 antagonists GALR3, GALR1, GALR2 NPSR1 123/4885ALDH1A1 3274/4885POLB 4358/4885
US-20100029624-A1 Male Contraceptive NR5A1, AR, CYP19A1 NPSR1 126/4885ALDH1A1 1598/4885POLB 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.